AU2001264612C1 - Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications - Google Patents
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications Download PDFInfo
- Publication number
- AU2001264612C1 AU2001264612C1 AU2001264612A AU2001264612A AU2001264612C1 AU 2001264612 C1 AU2001264612 C1 AU 2001264612C1 AU 2001264612 A AU2001264612 A AU 2001264612A AU 2001264612 A AU2001264612 A AU 2001264612A AU 2001264612 C1 AU2001264612 C1 AU 2001264612C1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- cell
- use according
- fragment
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/435992 | 1999-11-08 | ||
US21770600P | 2000-07-12 | 2000-07-12 | |
US60/217,706 | 2000-07-12 | ||
US09/772,938 US20020006404A1 (en) | 1999-11-08 | 2001-01-31 | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US09/772,938 | 2001-01-31 | ||
PCT/US2001/015677 WO2002004021A1 (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU22491/01A Division AU784174B2 (en) | 1999-11-08 | 2000-11-06 | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
Publications (4)
Publication Number | Publication Date |
---|---|
AU2001264612A1 AU2001264612A1 (en) | 2002-04-18 |
AU2001264612B2 AU2001264612B2 (en) | 2007-02-22 |
AU2001264612B8 AU2001264612B8 (en) | 2007-02-22 |
AU2001264612C1 true AU2001264612C1 (en) | 2007-11-22 |
Family
ID=26912176
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001264612A Ceased AU2001264612C1 (en) | 1999-11-08 | 2001-05-16 | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
AU6461201A Pending AU6461201A (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6461201A Pending AU6461201A (en) | 2000-07-12 | 2001-05-16 | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1305045A1 (xx) |
JP (1) | JP2004502742A (xx) |
KR (2) | KR20030031957A (xx) |
CN (1) | CN1446104A (xx) |
AU (2) | AU2001264612C1 (xx) |
CA (1) | CA2415100A1 (xx) |
IL (1) | IL153764A0 (xx) |
MX (1) | MXPA03000306A (xx) |
NO (1) | NO20030128L (xx) |
SG (1) | SG136804A1 (xx) |
WO (1) | WO2002004021A1 (xx) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1176981T3 (da) | 1999-05-07 | 2006-04-10 | Genentech Inc | Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer |
JP2004512262A (ja) * | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | 非放射性抗cd20抗体/放射標識抗cd22抗体の組合せ |
MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
DE60133479T2 (de) | 2000-10-20 | 2009-04-16 | Chugai Seiyaku K.K. | Modifizierter tpo-agonisten antikörper |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002060485A2 (en) * | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
WO2003068268A2 (en) * | 2002-02-14 | 2003-08-21 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
EP1609803A4 (en) * | 2003-03-31 | 2006-05-24 | Chugai Pharmaceutical Co Ltd | MODIFIED ANTIBODY AGAINST CD22 AND ITS USE |
SI1613350T1 (sl) | 2003-04-09 | 2009-08-31 | Genentech Inc | Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa |
EP1629001A2 (en) | 2003-06-05 | 2006-03-01 | Genentech, Inc. | Blys antagonists and uses thereof |
NZ546173A (en) | 2003-10-16 | 2009-04-30 | Micromet Ag | Multispecific deimmunized CD3-binders |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
CA2544368C (en) * | 2003-11-04 | 2014-04-01 | Chiron Corporation | Methods of therapy for b cell-related cancers |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
KR20070029733A (ko) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
JP5057967B2 (ja) | 2005-03-31 | 2012-10-24 | 中外製薬株式会社 | sc(Fv)2構造異性体 |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2006114115A1 (de) * | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
RU2421242C2 (ru) | 2005-07-25 | 2011-06-20 | Трабьон Фармасьютикалз, Инк. | Применение однократной дозы cd20-специфических связывающих молекул |
PT2298815E (pt) | 2005-07-25 | 2015-07-16 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
KR20080039999A (ko) | 2005-08-18 | 2008-05-07 | 젠맵 에이/에스 | Cd4 결합 펩티드 및 방사선을 이용한 치료 |
KR20080073725A (ko) | 2005-11-01 | 2008-08-11 | 노파르티스 아게 | 항-cd40 항체의 용도 |
US9726673B2 (en) | 2005-11-23 | 2017-08-08 | Genentech, Inc. | Methods and compositions related to B cell assays |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
WO2007124299A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Antagonist anti-cd40 antibody pharmaceutical compositions |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
KR20190140090A (ko) | 2007-07-09 | 2019-12-18 | 제넨테크, 인크. | 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지 |
DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
WO2009126944A1 (en) * | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
SG10201901417UA (en) | 2009-08-11 | 2019-03-28 | Genentech Inc | Production of proteins in glutamine-free cell culture media |
TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
AR080513A1 (es) | 2010-03-12 | 2012-04-11 | Inmunogen Inc | Moleculas de union cd37 y sus inmunoconjugados |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
DK3050896T3 (da) | 2013-09-27 | 2021-07-19 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af en polypeptid-heteromultimer |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
JP6979877B2 (ja) | 2015-06-08 | 2021-12-15 | デビオファーム インターナショナル, エス. アー. | 抗cd37イムノコンジュゲートおよび抗cd20抗体の組み合わせ |
CR20170562A (es) | 2015-06-24 | 2018-02-01 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
WO2017040247A1 (en) | 2015-08-28 | 2017-03-09 | Immunogen, Inc. | Antibodies and assays for detection of cd37 |
MY197562A (en) | 2015-09-21 | 2023-06-23 | Aptevo Res & Development Llc | Cd3 binding polypeptides |
EP3356406A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CA3003399A1 (en) | 2015-11-02 | 2017-05-11 | Bioatla, Llc | Conditionally active polypeptides |
JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Fc領域含有ポリペプチドの精製を効率化するための方法 |
EP3535297B1 (en) | 2016-11-02 | 2022-08-10 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
WO2018217918A2 (en) | 2017-05-24 | 2018-11-29 | Als Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
NZ258392A (en) * | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
-
2001
- 2001-05-16 SG SG200500152-4A patent/SG136804A1/en unknown
- 2001-05-16 AU AU2001264612A patent/AU2001264612C1/en not_active Ceased
- 2001-05-16 EP EP01939050A patent/EP1305045A1/en not_active Withdrawn
- 2001-05-16 MX MXPA03000306A patent/MXPA03000306A/es not_active Application Discontinuation
- 2001-05-16 KR KR10-2003-7000429A patent/KR20030031957A/ko not_active Application Discontinuation
- 2001-05-16 KR KR1020087009742A patent/KR20080039547A/ko not_active Application Discontinuation
- 2001-05-16 JP JP2002508475A patent/JP2004502742A/ja not_active Abandoned
- 2001-05-16 IL IL15376401A patent/IL153764A0/xx unknown
- 2001-05-16 CN CN01814063A patent/CN1446104A/zh active Pending
- 2001-05-16 AU AU6461201A patent/AU6461201A/xx active Pending
- 2001-05-16 WO PCT/US2001/015677 patent/WO2002004021A1/en active IP Right Grant
- 2001-05-16 CA CA002415100A patent/CA2415100A1/en not_active Abandoned
-
2003
- 2003-01-10 NO NO20030128A patent/NO20030128L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2415100A1 (en) | 2002-01-17 |
JP2004502742A (ja) | 2004-01-29 |
CN1446104A (zh) | 2003-10-01 |
IL153764A0 (en) | 2003-07-06 |
EP1305045A1 (en) | 2003-05-02 |
AU6461201A (en) | 2002-01-21 |
SG136804A1 (en) | 2007-11-29 |
NO20030128D0 (no) | 2003-01-10 |
KR20030031957A (ko) | 2003-04-23 |
KR20080039547A (ko) | 2008-05-07 |
WO2002004021A9 (en) | 2003-01-16 |
MXPA03000306A (es) | 2004-04-05 |
WO2002004021A1 (en) | 2002-01-17 |
NO20030128L (no) | 2003-03-12 |
AU2001264612B2 (en) | 2007-02-22 |
AU2001264612B8 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001264612C1 (en) | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications | |
US20020028178A1 (en) | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications | |
AU2002243718B2 (en) | Use of immunoregulatory antibodies in the treatment of neoplastic disorders | |
US6846476B2 (en) | Treatment of B-cell associated diseases | |
AU2001264612A1 (en) | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications | |
US20030103971A1 (en) | Immunoregulatory antibodies and uses thereof | |
AU2001259142C1 (en) | Intrathecal administration of rituximab for treatment of central nervous system lymphomas | |
US20020006404A1 (en) | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications | |
US20070003544A1 (en) | Combination therapy for treatment of autoimmune diseases using b- cell depleting/immunoregulatory antibody combination | |
AU2002243718A1 (en) | Use of immunoregulatory antibodies in the treatment of neoplastic disorders | |
EP2314318A1 (en) | CD80 antibody for use in combination with chemotherapeutics to treat B cell malignancies | |
AU2007234621B2 (en) | Use of immunoregulatory antibodies in the treatment of neoplastic disorders | |
JP2010059208A (ja) | 腫瘍疾患の治療における免疫調節性抗体の使用 | |
AU2007202671A1 (en) | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination | |
EP1328320A2 (en) | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TC | Change of applicant's name (sec. 104) |
Owner name: BIOGEN IDEC INC. Free format text: FORMER NAME: IDEC PHARMACEUTICALS CORPORATION |
|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 MAY 2007. |
|
FGA | Letters patent sealed or granted (standard patent) | ||
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 MAY 2007 |
|
TH | Corrigenda |
Free format text: IN VOL 21, NO 8, PAGE(S) 895 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME BIOGEN IDEC INC., APPLICATION NUMBER 2001264612, UNDER INID(62), CORRECT THE TERMS OF LETTERS PATENT TO READ 6 NOVEMBER 2000, UNDER INID (62) CORRECT THE PRIORITY DETAILS DIVISIONAL OF TO READ 784174 |
|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |